Home › Companies › OliX Pharmaceuticals

OliX Pharmaceuticals

올릭스 · 226950 · KOSDAQ
Filings, last 12 months
72
Supply contracts
0
Insider reports
10
Share & bond issues
2

At a glance

OliX Pharmaceuticals filed 72 disclosures in the last 12 months, including 10 insider, 7 5% holder and 2 issuance. The most recent key filing was on Sep 1.

The 2025 annual report lists 76 employees with an average tenure of 4.3 years and average pay of ₩198.2M, #7 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩489M each on average. It paid no cash dividend for 2025. 이동기 and related parties held 15.66% at year end.

From the 2025 annual report

Employees
76
Average pay
₩198.2M
Average tenure
4.3 yrs
Avg. director pay
₩489M

Staff: 76 (36 men, 40 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩14.1B. Directors and auditors: 8, paid ₩3.9B in total.

No cash dividend was paid for 2025.

Largest shareholder

이동기 holds 15.17%; with 14 related parties the group holds 15.66% of common shares at year end (from 19.52% at the start of the year).

Individuals paid ₩500M or more

이동기 대표이사₩1.5B
백영혜 부사장₩1.5B
이OO 직원₩877M
김OO 직원₩815M
이OO 직원₩747M

Auditor: 인덕회계법인 · opinion: Unqualified.

Rankings: Average pay #7 of 1,829

Source: 2025 annual business report (DART). How figures are combined

Financial summary

2023
Revenue -
Op. profit -₩18.2B
Debt/equity 104%
2024
Revenue -
Op. profit -₩30.9B
Debt/equity 286%
2025
Revenue -
Op. profit -₩30B
Debt/equity 30%
2026 H1
Revenue -
Op. profit -₩24.8B
Debt/equity 15%
RevenueOperating profitOperating lossConsolidated where available · from periodic reports

Key filings

Other filings

Links open the original filing on DART, in Korean.